Evaluation of SARS-CoV-2 Antibody Response Post Third Dose COVID-19 mRNA Vaccination at Universitas Indonesia Hospital

Authors

  • Rakhmad Hidayat Faculty of Medicine Universitas Indonesia; Dr. Cipto Mangunkusumo Hospital; Universitas Indonesia Hospital
  • Alyssa Putri Mustika Faculty of Medicine Universitas Indonesia; Dr. Cipto Mangunkusumo Hospital; Universitas Indonesia Hospital
  • Fhathia Avisha Universitas Indonesia Hospital
  • Zlatikha Djuliannisaa Faculty of Medicine Universitas Indonesia; Dr. Cipto Mangunkusumo Hospital
  • Dinisa Diah Winari Universitas Indonesia Hospital
  • Ria Amiliah Putri Universitas Indonesia Hospital
  • Heydi Marizky Lisman Universitas Indonesia Hospital
  • Vandra Davin Universitas Indonesia Hospital
  • Gemia Clarisa Fathi Universitas Indonesia Hospital
  • Alvina Widhani Faculty of Medicine Universitas Indonesia; Dr. Cipto Mangunkusumo Hospital; Universitas Indonesia Hospital
  • Muhammad Hafiz Aini Faculty of Medicine Universitas Indonesia; Dr. Cipto Mangunkusumo Hospital; Universitas Indonesia Hospital
  • Yudhistira Yudhistira Universitas Indonesia Hospital
  • Siti Azizah Faculty of Medicine Universitas Indonesia; Universitas Indonesia Hospital
  • Meilisa Rahmadani Universitas Indonesia Hospital
  • Novita Dwi Istanti Universitas Indonesia Hospital
  • Astuti Giantini Faculty of Medicine Universitas Indonesia; Dr. Cipto Mangunkusumo Hospital; Universitas Indonesia Hospital

DOI:

https://doi.org/10.5644/ama2006-124.374

Keywords:

COVID-19, SARS-CoV-2, Vaccine

Abstract

Objective. The longevity of vaccine effectiveness and antibody titer after the Moderna mRNA COVID-19 vaccination booster in healthcare workers in Indonesia is not known.

Materials and Methods. We performed a prospective observational study of healthcare workers at the Universitas Indonesia Hospital after Moderna mRNA COVID-19 booster vaccination. An Immunology Analyzer with Chemiluminescence Immunoassay (CLIA) test was used to examine Anti SARS-CoV-2 S-RBD levels. Antibody levels were classified into two systems (3 categories, and 2 categories).

Results. There were 31 male subjects (75.6%), 33 subjects (80.5%) aged 25-39 years, 17 subjects (41.5%) with overweight BMI, 35 subjects (85.4%) without comorbidities, and 29 subjects without previous history of COVID-19 infection (70.7%) who had antibody titer >1000 AU/ml. There were 27 subjects (65.9%) who had a booster shot ≥6 months after the second vaccination with antibody titer >1000 AU/ml. In this study, there was no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination.

Conclusion. There is no significant correlation between antibody titer with factors such as gender, age, BMI, comorbidities, history of COVID-19 infection and time between the 2nd vaccination and booster vaccination

Downloads

Download data is not yet available.

Downloads

Published

2022-12-16

How to Cite

Hidayat, R., Mustika, A. P., Avisha, F., Djuliannisaa, Z., Winari, D. D., Putri, R. A., Lisman, H. M., Davin, V., Fathi, G. C., Widhani, A., Aini, M. H., Yudhistira, Y., Azizah, S., Rahmadani, M., Istanti, N. D., & Giantini, A. (2022). Evaluation of SARS-CoV-2 Antibody Response Post Third Dose COVID-19 mRNA Vaccination at Universitas Indonesia Hospital. Acta Medica Academica, 51(2), 69–78. https://doi.org/10.5644/ama2006-124.374

Issue

Section

Clinical Medicine

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.